Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Positive long-term results from the company's ongoing HOPE-2 open label extension ("OLE") clinical trial were announced today by Capricor Therapeutics, a biotechnology company that...
ITF Therapeutics LLC Presents Long-Term Data of DUVYZAT™ (givinostat) for Treatment of Duchenne Muscular Dystrophy at MDA Clinical and Scientific Conference
Today, Italfarmaco's U.S. affiliate, ITF Therapeutics LLC, announced seven abstracts for the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Dallas, Texas, March...
Avidity Biosciences Announces Positive Topline Del-zota Data Showing Consistent, Statistically Significant Improvements in Dystrophin
Avidity Biosciences Announces Positive Topline Del-zota Data Showing Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping, and Creatine Kinase in Phase 1/2 EXPLORE44® Trial...
Roche to Share Ongoing Work on Elevidys Gene Therapy at Muscular Dystrophy Association (MDA) 2025 Conference
At the Muscular Dystrophy Association (MDA) 2025 Conference, Roche will discuss their ongoing work on Elevidys Gene Therapy.Late-breaking oral on Elevidys’ Embark two-year data...
Dyne Therapeutics Announces Unprecedented and Sustained Functional Improvement Through 18 Months from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy
Dyne Therapeutics, a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced new long-term clinical data...